Competition created in part by biosimilars has led to significant savings for the healthcare system, potentially allowing these savings to be deployed to newer, innovative treatments. Take a deeper dive into the latest data in the eighth edition of Amgen’s Biosimilar Trends Report, which examines the current state of the biosimilars marketplace across oncology, inflammation, and nephrology. It also outlines relevant policy and reimbursement updates that impact biosimilar adoption and utilization, as well as key considerations for providers, payers, and policymakers.  REVIEW REPORT